达拉非尼联合曲美替尼治疗ALK与BRAF基因双突变晚期肺腺癌1例  

A Case of Advanced Lung Adenocarcinoma with ALK and BRAF Mutations Treated with Dabrafenib Plus Trametinib

作　　者：伍越 张思佳 镇鸿燕[1] 龙志雄 WU Yue;ZHANG Sijia;ZHEN Hongyan;LONG Zhixiong(School of Medicine,Jianghan University,Wuhan 430056,Hubei,China;Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430021,Hubei,China;De-partment of Oncology,The Fifth Hospital in Wuhan,Wuhan 430050,Hubei,China)

机构地区：[1]江汉大学医学部,湖北武汉430056 [2]华中科技大学同济医学院附属协和医院肿瘤中心,湖北武汉430021 [3]武汉市第五医院肿瘤科,湖北武汉430050

出　　处：《江汉大学学报（自然科学版）》2024年第2期28-33,共6页Journal of Jianghan University：Natural Science Edition

摘　　要：目的ALK与BRAF基因双突变在非小细胞肺癌(non-small cell lung cancer,NSCLC)中极为罕见,目前有效的治疗方案尚缺乏临床案例及数据支持,本报道期望为该类患者的治疗提供临床参考。方法报道1例ALK融合与BRAF突变并存的86岁的女性晚期肺腺癌病例,给予达拉非尼联合曲美替尼方案的治疗。结果该患者经达拉非尼联合曲美替尼方案治疗后疗效评价达部分缓解(partial response,PR),且治疗过程中并未出现严重不良反应。结论随着基因检测技术的发展及生物靶向药物的开发,晚期NSCLC患者生存率和生活质量得到提升。该例患者对达拉非尼联合曲美替尼方案有确切疗效,对ALK与BRAF基因双突变NSCLC临床诊治有参考意义。Objective Coexisting ALK and BRAF mutations are extremely rare in nonsmall cell lung cancer(NSCLC),and effective treatment options are not yet supported by clinical cases and data,thus this report is expected to provide a clinical reference for treating this group of patients.Methods To report a case of advanced lung adenocarcinoma in an 86-year-old female with coexisting ALK fusion and BRAF mutation,who was treated with dabrafenib plus trametinib.Results In our case,the patient achieved partial response(PR)after the treatment,and no serious adverse reactions were observed during the treatment.Conclusion With the rapid development of gene detection technology and biotargeted drugs,the survival rate and life quality of patients with advanced NSCLC have been improved.This patient showed definite efficacy for dabrafenib plus trametinib,which provides a significant reference to the clinical diagnosis and treatment of NSCLC with ALK and BRAF mutations.

关 键 词：非小细胞肺癌 ALK融合 BRAF突变 靶向治疗 病例报告 

分 类 号：R734.2[医药卫生—肿瘤]